Profile data is unavailable for this security.
About the company
Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.
- Revenue in USD (TTM)36.86m
- Net income in USD-171.67m
- Incorporated2001
- Employees123.00
- LocationMersana Therapeutics Inc840 Memorial DrCAMBRIDGE 02139-3789United StatesUSA
- Phone+1 (617) 498-0020
- Fax+1 (302) 655-5049
- Websitehttps://www.mersana.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revance Therapeutics Inc | 234.04m | -323.99m | 395.50m | 534.00 | -- | -- | -- | 1.69 | -3.81 | -3.81 | 2.77 | -1.72 | 0.4414 | 2.33 | 12.00 | -- | -61.11 | -55.55 | -72.36 | -63.20 | 68.23 | -- | -138.43 | -304.96 | 3.29 | -36.36 | 1.54 | -- | 76.55 | 128.84 | 9.10 | -- | -0.3022 | -- |
Replimune Group Inc | 0.00 | -209.96m | 397.79m | 284.00 | -- | 0.9437 | -- | -- | -3.16 | -3.16 | 0.00 | 6.87 | 0.00 | -- | -- | 0.00 | -34.66 | -26.12 | -36.63 | -27.31 | -- | -- | -- | -- | -- | -- | 0.1436 | -- | -- | -- | -47.65 | -- | 75.59 | -- |
Cartesian Therapeutics Inc | 26.00m | -219.71m | 402.90m | 38.00 | -- | -- | -- | 15.49 | -41.77 | -41.77 | 5.03 | -25.87 | 0.1104 | -- | 4.17 | 684,315.80 | -93.31 | -43.66 | -116.36 | -66.84 | -- | -- | -844.91 | -136.35 | -- | -0.5814 | -- | -- | -76.53 | 95.83 | -721.02 | -- | -25.27 | -- |
Tourmaline Bio Inc | 0.00 | -42.12m | 402.91m | 44.00 | -- | 1.56 | -- | -- | -10.18 | -10.18 | 0.00 | 10.08 | 0.00 | -- | -- | 0.00 | -20.85 | -- | -21.74 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
Lenz Therapeutics Inc | 0.00 | -124.65m | 403.70m | 6.00 | -- | 0.7137 | -- | -- | -15.35 | -15.35 | 0.00 | 22.15 | 0.00 | -- | -- | 0.00 | -48.85 | -- | -50.62 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
Contineum Therapeutics Inc | 50.00m | 22.72m | 404.20m | 31.00 | 17.09 | -- | 17.61 | 8.08 | 0.9041 | 0.9041 | 1.99 | 4.96 | -- | -- | -- | 1,612,903.00 | -- | -- | -- | -- | -- | -- | 45.44 | -- | -- | -- | 0.00 | -- | -- | -- | 193.68 | -- | -- | -- |
Adaptive Biotechnologies Corp | 170.28m | -225.25m | 404.81m | 709.00 | -- | 1.31 | -- | 2.38 | -1.56 | -1.56 | 1.18 | 2.13 | 0.2244 | 5.23 | 4.36 | 240,163.60 | -29.69 | -19.69 | -34.13 | -22.06 | 55.63 | 67.18 | -132.32 | -122.27 | 4.50 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
Lexeo Therapeutics Inc | 0.00 | -66.39m | 405.25m | 58.00 | -- | 2.89 | -- | -- | -2.69 | -2.69 | 0.00 | 4.26 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0153 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
Lexicon Pharmaceuticals Inc | 1.21m | -177.12m | 406.29m | 285.00 | -- | 4.34 | -- | 337.17 | -0.7975 | -0.7975 | 0.0055 | 0.3802 | 0.0057 | -- | 2.32 | 4,228.07 | -83.60 | -24.41 | -96.00 | -29.01 | 90.95 | 98.49 | -14,698.67 | -84.92 | 5.58 | -13.11 | 0.5166 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
OraSure Technologies, Inc. | 405.47m | 53.66m | 407.80m | 638.00 | 7.40 | 0.91 | 5.47 | 1.01 | 0.7204 | 0.7204 | 5.47 | 5.86 | 0.8748 | 3.15 | 7.31 | 635,536.10 | 11.58 | 0.7238 | 13.11 | 0.8212 | 44.25 | 46.94 | 13.23 | 1.13 | 8.57 | -- | 0.0018 | 0.00 | 4.64 | 17.41 | 413.17 | 82.20 | 10.18 | -- |
Mersana Therapeutics Inc | 36.86m | -171.67m | 408.79m | 123.00 | -- | 11.02 | -- | 11.09 | -1.50 | -1.50 | 0.3175 | 0.3057 | 0.1315 | -- | 2.46 | 299,634.20 | -61.27 | -61.68 | -84.73 | -81.35 | -- | -- | -465.80 | -622.19 | -- | -- | 0.408 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
Tscan Therapeutics Inc | 21.05m | -89.22m | 412.94m | 154.00 | -- | 2.73 | -- | 19.62 | -2.49 | -2.49 | 0.4421 | 3.15 | 0.0893 | -- | -- | 136,681.80 | -37.87 | -- | -42.07 | -- | -- | -- | -423.86 | -- | -- | -- | 0.1661 | -- | 55.52 | -- | -34.73 | -- | -- | -- |
Biomea Fusion Inc | 0.00 | -117.26m | 415.24m | 103.00 | -- | 2.45 | -- | -- | -3.46 | -3.46 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -71.23 | -- | -81.63 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
ACELYRIN Inc | 0.00 | -381.64m | 420.38m | 130.00 | -- | 0.6337 | -- | -- | -10.84 | -10.84 | 0.00 | 6.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
iTeos Therapeutics Inc | 12.60m | -112.64m | 423.67m | 157.00 | -- | 0.7339 | -- | 33.64 | -3.15 | -3.15 | 0.3522 | 16.05 | 0.0177 | -- | 2.82 | 80,222.93 | -15.84 | 5.84 | -16.81 | 7.02 | -- | -- | -894.35 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
Cibus Inc | 1.82m | -267.63m | 423.73m | 183.00 | -- | 1.20 | -- | 233.21 | -22.63 | -22.63 | 0.1769 | 14.27 | 0.0064 | -- | -- | 9,928.96 | -119.13 | -86.28 | -135.32 | -96.45 | 2.31 | -- | -18,582.22 | -792.07 | -- | -3.70 | 0.0049 | -- | 1,057.33 | 50.41 | -1,484.44 | -- | 18.53 | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Dec 2023 | 19.36m | 15.96% |
Balyasny Asset Management LPas of 31 Dec 2023 | 9.70m | 8.00% |
BlackRock Fund Advisorsas of 31 Dec 2023 | 7.02m | 5.79% |
SilverArc Capital Management LLCas of 31 Dec 2023 | 6.42m | 5.29% |
The Vanguard Group, Inc.as of 31 Dec 2023 | 6.07m | 5.00% |
Morgan Stanley & Co. LLCas of 31 Dec 2023 | 4.13m | 3.40% |
Millennium Management LLCas of 31 Dec 2023 | 3.39m | 2.80% |
Rock Springs Capital Management LPas of 31 Dec 2023 | 3.05m | 2.51% |
Acuta Capital Partners LLCas of 31 Dec 2023 | 2.37m | 1.95% |
SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.33m | 1.92% |